Introduction {#s1}
============

Osteoarthritis (OA) is a prevalent, complex, disabling disease of articular joints, characterised by degradation of articular cartilage and remodelling of the subchondral bone. There is no effective therapy to reverse or slow down the disease except for joint replacement surgery at the end stage. As a result, OA has a large detrimental impact on the quality of life of the elderly and causes a major burden on health and social care.[@R1] To allow development of new therapies, there is an ongoing need for insight into the underlying mechanisms driving OA. Genetic studies provided evidence that genes orchestrating growth plate endochondral ossification play a underlying role in common OA susceptibility,[@R2] hence functional follow-up approaches require focus on both the early developmental and late-acting effects of these OA genes. A notable example is the deiodinase iodothyronine type 2 (D2) gene (*DIO2*) with the C-allele of the single nucleotide polymorphism (SNP) rs225014 (frequency ∼ 0.35) located in the coding region that conferred consistent risk to OA.[@R3] [@R4] The gene product of *DIO2* is responsible for catalysing the conversion of intracellular inactive thyroid hormone (T4) to active thyroid hormone (T3). T3 subsequently signals terminal maturation of growth plate chondrocytes leading to cell hypertrophy, cartilage matrix destruction mediated via upregulation of hypoxia inducible factor-2α (*HIF-2α*) and runt-related transcription factor-2 (*RUNX2*),[@R5] [@R6] mineralisation of the cartilage and eventually formation of bone.[@R7] There are striking parallels between the chondrocyte signalling events that take place in the growth plate and those of hypertrophic chondrocytes in OA-affected articular cartilage.[@R5] This has led to the hypothesis that with age and environmental stresses the propensity of the highly specialised, maturational arrested articular chondrocytes is affected by loss of epigenic control. Progression of age and disease could result in reactivation of genes involved in endochondral ossification, leading to loss and mineralisation of articular cartilage, a process known to contribute to OA.[@R3] [@R8] Functional genomic studies showed high expression of *DIO2* mRNA and D2 protein levels in osteoarthritic as compared with healthy cartilage.[@R5] [@R11] [@R12] Furthermore, *DIO2* allelic imbalance was assessed and showed that the OA risk allele 'C' was more abundantly present in articular joint tissues than the wildtype allele 'T'.[@R11] In transgenic rats, *DIO2* overexpression conferred risk to articular cartilage destruction.[@R13] The underlying mechanism how the *DIO2* SNP confers susceptibility to OA in humans remains, however, to be determined,[@R14] but most likely acts via aberrant upregulation of its expression. The *DIO2* locus in humans contains several putative CCCTC-binding factor (CTCF) binding sites, including one that is overlapping with the rs225014 location.[@R15] CTCF is considered to facilitate long-range chromatin interactions in order to insulate gene expression, and distal transcriptional elements on the genome are brought in close proximity to transcriptional start sites (TSSs) of genes to inhibit expression.[@R16]

In the current study, we focus on regulatory mechanisms of *DIO2* expression in preserved and osteoarthritic human articular cartilage, thereby taking into account the *DIO2* risk allele. The direct effect of changes in *DIO2* expression on chondrocyte function and human cartilage extracellular matrix (ECM) homeostasis is subsequently studied in human in vitro chondrogenesis models, which should be considered a well-defined system for studying changes in the ECM when chondrocytes differentiate, become hypertrophic and start to exhibit cartilage-debilitating expression patterns.

Materials and methods {#s2}
=====================

The ongoing RAAK study is aimed at the biobanking of joint materials (cartilage, bone and, where available, ligaments) and mesenchymal stem cells and primary chondrocytes of patients in the Leiden University Medical Center. In the current study, we used paired preserved and OA-affected cartilage samples from 52 Caucasian end-stage OA patients undergoing joint replacement surgery for primary OA (23 hips, 29 knees). For additional details on the RAAK study, cell cultures, RNA and DNA extraction, quantitative RT-PCR, ChIP and the data analysis, see online supplemental methods.

Electrophoretic mobility shift assay {#s2a}
------------------------------------

For electrophoretic mobility shift assays (EMSAs), synthetic oligonucleotides containing the putative CTCF binding site were 5′-end labelled by γ-^32^P-ATP and subsequently purified by gel filtration on Sephadex G-25 Medium columns. For additional details, see online supplemental methods.

Quantification of methylation {#s2b}
-----------------------------

The methylated fraction of CpG dinucleotides was assessed with MALDI-TOF mass spectrometry (Epityper, Sequenom), a commonly applied method to quantify CpG methylation.[@R17] For additional details, see online supplemental methods.

Lentiviral constructs and transduction {#s2c}
--------------------------------------

C-terminal FLAG-tagged cys-D2 (kindly provided by Prof. Dr. Bianco[@R20]) was digested with *Eco*RI followed by Klenow treatment and digestion with *Xba*I. Inserts were inserted into the *Eco*RV*-Xba*I sites of the pLV-CMV-IRES-eGFP Lentiviral backbone. For additional details, see online supplemental methods.

In vitro chondrogenesis {#s2d}
-----------------------

3D pellets were formed using 2.5×10^5^ human bone marrow-derived mesenchymal stem cells (hBMSCs). Chondrogenesis was initiated in serum-free chondrogenic differentiation medium. From day 14 onwards, cell pellets were maintained either in the standard chondrogenic differentiation medium or in the presence of T~3~ (10 nM) or IOP (10 μM). For additional details, see online supplemental methods.

Relative pixel intensity {#s2e}
------------------------

The relative pixel intensity was computed by loading the photos into ImageJ (V.1.47).[@R21] For additional details, see online supplemental methods.

Results {#s3}
=======

Epigenetic regulation of *DIO2* expression by CpG methylation in articular cartilage {#s3a}
------------------------------------------------------------------------------------

Online available ChIP-seq data revealed multiple transcription factors to bind the rs225014 locus of which CTCF was predicted to bind with the highest certainty (see online supplementary figure S1). To assess the regulatory properties of the CTCF binding site overlapping rs225014 and to test whether the rs225014 alleles directly affect the binding, we performed an EMSA. The putative CTCF sequence overlapping rs225014 (DIO2-CTCF1) was found not functional nor, for that matter, dependent of the rs225014 alleles (see online supplementary figure S2, lanes 1--6).

As no further TFs were confidently predicted to bind the rs225014 locus, we set out to elucidate putative regulatory mechanisms of *DIO2*, independent of the rs225014 base change. We, therefore, quantified expression of *DIO2* and methylation of 23 CpG dinucleotides across the *DIO2* locus in macroscopically preserved and OA-affected cartilage from joints of patients undergoing total arthroplasty of the knee (N=29) or hip (N=23) (RAAK study; see online supplementary table S1). We found borderline significant upregulation of *DIO2* expression (β=0.22, p=0.063, [figure 1](#ANNRHEUMDIS2013204739F1){ref-type="fig"}C) in OA compared with preserved cartilage. Furthermore, we observed several CpG dinucleotides to be differentially methylated between preserved and OA-affected cartilage (see online supplementary table S2). However, only for the CpG site 2031 base pairs upstream of the *DIO2* transcription start site (CpG-2031, [figure 1](#ANNRHEUMDIS2013204739F1){ref-type="fig"}A) we observed significant differential methylation between OA and preserved cartilage (β=0.028, p=0.0007, [figure 1B](#ANNRHEUMDIS2013204739F1){ref-type="fig"}) and a significant positive association between methylation and *DIO2* expression in all samples (β=4.959, p=0.0016, [figure 1](#ANNRHEUMDIS2013204739F1){ref-type="fig"}D; see online supplementary table S2). To confirm the regulatory properties of CpG-2031 on *DIO2* expression, we applied 5-aza-2′-deoxycytidine (AZA), a demethylating agent, to the culture medium in eight primary chondrocyte cultures derived from preserved cartilage of total hip replacement patients. Addition resulted in a decrease in methylation at CpG-2031 (p=0.003, [figure 2](#ANNRHEUMDIS2013204739F2){ref-type="fig"}A) corresponding to downregulation of *DIO2* expression (p=0.004, [figure 2](#ANNRHEUMDIS2013204739F2){ref-type="fig"}B). Having observed the association between *DIO2* expression and OA-associated methylation at CpG-2031, we applied a multivariate model to assess the individual effects of CpG-2031 methylation, joint site, sex, BMI, age and rs225014 alleles on *DIO2* expression in articular cartilage (see online supplementary table S3). We could hereby ratify the association between increased CpG-2031 methylation and *DIO2* expression (β=4.008, p=0.019). The most notable observation, however, was the significant independent association of rs225014 genotype on *DIO2* expression (β=0.557, p=0.0003), indicating additive effects of both genotype and DNA methylation differences on *DIO2* expression. This effect appeared to be mainly driven by the risk allele. Upon stratification by the rs225014 alleles, no significant differences were observed between preserved and OA-affected cartilage among homozygous carriers of the rs225014 wildtype allele T in methylation (β=0.018, p=0.112, [figure 1](#ANNRHEUMDIS2013204739F1){ref-type="fig"}E) or expression (β=−0.017, p=0.929, [figure 1](#ANNRHEUMDIS2013204739F1){ref-type="fig"}F). In carriers of the risk allele, however, an increase was observed in OA cartilage compared with the preserved tissue, both in the difference of CpG-2031 methylation (β=0.034, p=0.00002, [figure 1](#ANNRHEUMDIS2013204739F1){ref-type="fig"}H) and in expression (β=0.35, p=0.012, [figure 1](#ANNRHEUMDIS2013204739F1){ref-type="fig"}I), concomitant with an increased association between methylation and expression (β=6.816, p=0.00001, [figure 1](#ANNRHEUMDIS2013204739F1){ref-type="fig"}J). As expected, this association between expression and methylation was much smaller among homozygous wildtype allele carriers (β=3.863, p=0.050, [figure 1](#ANNRHEUMDIS2013204739F1){ref-type="fig"}G).

![A functional CpG dinucleotide (CpG-2031) significantly modulates *DIO2* expression. (A) Schematic overview of the quantified CpG dinucleotides in pooled preserved and paired osteoarthritis (OA)-affected samples across the *DIO2* locus. (B) Methylation between preserved and OA-affected samples for CpG dinucleotide located 2031 base pairs upstream (CpG-2031) of the *DIO2* transcriptional start site (TSS) (GLMM, N=103, β=0.028, p=0.001, Bonferroni adjusted; see also online [supplementary table](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204739/-/DC1) S2). (C) Real-time qRT-PCR data of *DIO2* expression between preserved and OA-affected cartilage (GLMM, N=87, β=0.22, p=0.063). (D) Association between methylation at CpG-2031 and *DIO2* expression (GLMM, N=87, β=4.959, p=0.002, Bonferroni adjusted for 23 CpG sites tested). (E) Methylation between preserved and OA-affected cartilage for CpG-2031 among homozygous rs225014 wildtype allele carriers (GLMM, N=44, β=0.018, p=0.112). (F) Real-time qRT-PCR data of *DIO2* expression between preserved and OA-affected cartilage among homozygous rs225014 wildtype allele carriers (GLMM, N=36, β=−0.017, p=0.929). (G) Association between methylation at CpG-2031 and *DIO2* expression among homozygous rs225014 wildtype allele carriers (GLMM, N=36, β=3.863, p=0.050). (H) Methylation between preserved and OA-affected cartilage for CpG-2031 among the heterozygous and homozygous carriers of the rs225014 risk allele (GLMM, N=59, β=0.034, p=0.00002). (I) Real-time qRT-PCR data of *DIO2* expression between preserved and OA-affected cartilage among rs225014 risk allele carriers (GLMM, N=51, β=0.35, p=0.012). (J) Association between methylation at CpG-2031 and *DIO2* expression among rs225014 risk allele carriers (GLMM, N=51, β=5.58, p=0.0006). \*p\<0.05, \*\*p\<0.01, \*\*\*p\< 0.001. OA,  osteoarthritic cartilage; P, preserved cartilage.](annrheumdis-2013-204739f01){#ANNRHEUMDIS2013204739F1}

![Methylation regulates *DIO2* expression in articular cartilage. Each pair of bars reflects a unique donor cell culture, derived from total hip replacement patients. (A) Methylation at dinucleotide CpG-2031 without treatment (Control) and after treatment with 1.5 µM of the demethylating agent 5-aza-2-deoxycytidine (AZA). (B) Real-time qRT-PCR data of *DIO2* expression without treatment and after AZA treatment.](annrheumdis-2013-204739f02){#ANNRHEUMDIS2013204739F2}

*DIO2* effects on in vitro chondrogenesis; *DIO2* overexpression {#s3b}
----------------------------------------------------------------

To assess the direct effect of *DIO2* upregulation upon cartilage matrix homeostasis, we examined in vitro chondrogenesis of hBMSCs in a pellet culture for five consecutive weeks and generated lentiviral-mediated overexpression of *DIO2* ([figure 3](#ANNRHEUMDIS2013204739F3){ref-type="fig"}A and online supplementary figure S3). As a result, we observed a greatly reduced expression of genes encoding the main proteins of articular cartilage ECM, *COL2A1*, *ACAN* and *COL10A1* by reverse transcriptase qPCR (p\<0.0001; [figure 3](#ANNRHEUMDIS2013204739F3){ref-type="fig"}A). In parallel, we observed profound and significant upregulated gene expression of the OA markers of hypertrophy and ECM breakdown *ADAMTS5*, *MMP13, RUNX2* and *EPAS1* (encoding HIF-2α) from 3 weeks onwards (p\<0.05, [figure 3](#ANNRHEUMDIS2013204739F3){ref-type="fig"}A). Histology confirmed a reduced deposition of glycosaminoglycans (GAGs) ([figure 3](#ANNRHEUMDIS2013204739F3){ref-type="fig"}B,C). Although we did not have data to apply proper statistics to produce a significant number, pixel intensity measurements of the pictures reproduced as in [figure 3](#ANNRHEUMDIS2013204739F3){ref-type="fig"}B,C showed us a 35% difference after 35 days between control and *DIO2* overexpressing pellets, concurrent with visual lower collagen type II (COL2) and collagen type X (COL10) protein expression by immunohistochemical staining at consecutive weeks compared with controls ([figure 3](#ANNRHEUMDIS2013204739F3){ref-type="fig"}D--G).

![Overexpressing *DIO2* has a detrimental effect on cartilage extracellular matrix homeostasis. (A) qRT-PCR analysis of *DIO2, COL2A1, ACAN, COL10A1, RUNX2, EPAS1, MMP13, ADAMTS5* and *ALPL* at 21 and 35 days of treatment in the chondrogenic human bone marrow-derived stem cells (hBMSC) transduced with respectively control vector (eGFP) and DIO2 (DIO2_eGFP; see online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204739/-/DC1) S3). (B--G) Sections comparing control (top) and *DIO2* overexpressing (bottom) chondrogenic hBMSC pellets at 21 and 35 days of treatment. (B, C) Alcian blue staining. (D, E) Immunohistochemical staining of collagen type II. (F, G) Immunohistochemical staining of collagen type X. (B, D and F) Scale bar, 400 μm. (C, E and G) Scale bar, 100 μm. The expression levels were arbitrarily defined as '1' in the pellets grown under control conditions (white), and data from the pellets overexpressing *DIO2* (black) are given as mean±SEM. *\**p\<0.05, *\*\*p*\<0.01, *\*\*\*p*\<0.001. SEM\<0.05 are not distinguishable in the figure.](annrheumdis-2013-204739f03){#ANNRHEUMDIS2013204739F3}

*DIO2* effects on in vitro chondrogenesis; thyroid hormone signalling {#s3c}
---------------------------------------------------------------------

To explore whether the effects of *DIO2* overexpression are due to enhanced thyroid signalling, we examined in vitro chondrogenesis of hBMSCs from five different donors (see online supplementary table S4) in pellet cultures for seven consecutive weeks (see online supplementary figure S4) while adding active T3 to the chondrogenic medium from two weeks onwards ([figure 4](#ANNRHEUMDIS2013204739F4){ref-type="fig"}A--F). Excess T3 resulted in a significant, progressive reduction in pellet sizes compared with controls, at consecutive weeks of culturing (p\<0.05, [figure 4](#ANNRHEUMDIS2013204739F4){ref-type="fig"}G). Respective expression analyses showed a reduced expression of the ECM genes *ACAN* and *COL2A1* ([figure 4](#ANNRHEUMDIS2013204739F4){ref-type="fig"}J), although the downregulation of *COL2A1* appeared not statistically significant. Assessing the chondrogenic potential by measuring the ratio between *COL2A1* and *COL1A1* expression showed a dramatic effect on the chondrogenic effect of the cell system upon addition of T3 ([figure 4](#ANNRHEUMDIS2013204739F4){ref-type="fig"}I). Moreover, the OA markers of hypertrophy and ECM breakdown genes *ADAMTS5*, *RUNX2* and *EPAS1* were consistently upregulated from 3 weeks of treatment onwards across the donor cultures (p\<0.05, [figure 4](#ANNRHEUMDIS2013204739F4){ref-type="fig"}J). The differences in mean expression of *MMP13* between controls and T3-treated cells across the donors at consecutive time points were not significant. Immunohistochemical studies contributed to the confirmation that excess T3 resulted in a reduced expression of COL2 ([figure 4](#ANNRHEUMDIS2013204739F4){ref-type="fig"}C,D) and COL10 ([figure 4](#ANNRHEUMDIS2013204739F4){ref-type="fig"}E,F) and a pronounced reduction of GAGs ([figure 4](#ANNRHEUMDIS2013204739F4){ref-type="fig"}A,B) as reflected by the reduced Alcian blue staining at consecutive time points with an overall mean decrease of 35% (p=0.0002) as measured by the quantitative pixel intensities ([figure 4](#ANNRHEUMDIS2013204739F4){ref-type="fig"}H).

![Thyroid hormone is believed to be a key regulator in human cartilage development. (A--F) Sections of a representative donor (see online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204739/-/DC1) S4) comparing control (top) and T3-treated (bottom) chondrogenic human bone marrow-derived stem cell (hBMSC) pellets at 7, 21 and 35 days of treatment. (A, B) Alcian blue staining. (C, D) Immunohistochemical staining of collagen type II. (E, F) Immunohistochemical staining of collagen type X. (A, C and E) Scale bar, 400 μm. (B, D and F) Scale bar, 100 μm. (G) Mean surface area measurements at 7, 21 and 35 days of treatment with N=3 donors in each group. (H) Mean quantitative pixel-intensity measurements (see online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204739/-/DC1) S5) at 7, 21 and 35 days of treatment with N=5 donors in each group. (I) Log2 ratio of *COL2A1* and *COL1A1* with N=5 donors in each group. (J) Mean real-time qRT-PCR analysis of *COL2A1*, *ACAN*, *COL10A1*, *COL1A1, ALPL, ADAMTS5 MMP13*, *RUNX2* and *EPAS1* at 7, 21 and 35 days of treatment in chondrogenic hBMSCs of N=5 donors in each group. The surface area measurement, pixel intensities and level of expression were arbitrarily defined as '1' in the pellets grown under control conditions (white) and the data from the pellets grown in the addition of excess T3 (black) are given as mean±SEM. *\**p\<0.05, *\*\**p\<0.01, *\*\*\**p\<0.001. SEM\<0.05 are not distinguishable in the figure.](annrheumdis-2013-204739f04){#ANNRHEUMDIS2013204739F4}

Pharmacological inhibition of D2 {#s3d}
--------------------------------

To investigate whether thyroid signalling blockade attenuates the detrimental effect on cartilage matrix homeostasis, pellet cultures were treated with the pharmacological deiodinase inhibitor iopanoic acid (IOP) during in vitro chondrogenesis of hBMSCs of the five donors. Quantification of surface areas indicated increasing sizes at consecutive time points in the IOP-treated pellets comparable to non-treated, control pellets ([figure 5G](#ANNRHEUMDIS2013204739F5){ref-type="fig"}). Respective expression analyses showed a significantly increased expression of the ECM genes *ACAN, COL2A1* and *COL10A1* after 3 weeks of treatment (p\<0.01, [figure 5](#ANNRHEUMDIS2013204739F5){ref-type="fig"}J), whereas the OA markers of hypertrophy and ECM breakdown genes *ADAMTS5*, *RUNX2* and *EPAS1* were similar to control cultures ([figure 5](#ANNRHEUMDIS2013204739F5){ref-type="fig"}J). Furthermore, we found no significant difference in chondrogenic potential between control and IOP-treated pellets when assessing the ratio between *COL2A1* and *COL1A1* expression ([figure 5](#ANNRHEUMDIS2013204739F5){ref-type="fig"}I). Following these expression patterns, histological analysis of matrix components showed slightly higher levels of COL2 and COL10 staining ([figure 5](#ANNRHEUMDIS2013204739F5){ref-type="fig"}C--F) and higher levels of GAGs as reflected by a significant 4% increase in Alcian blue staining at week 5 of treatment (p=0.018; [figure 5](#ANNRHEUMDIS2013204739F5){ref-type="fig"}A,B and H). Of note is the denser cartilage matrix structure with less cellular lacunae at week 5 of treatment in cells treated with IOP compared with controls ([figure 5](#ANNRHEUMDIS2013204739F5){ref-type="fig"}A). By discriminating 'cartilage' from the 'lacunae' using the ImageJ data, we could show that administration of IOP resulted in a 10.92% decrease of lacunae (p=4.27×10^−5^) on day 35 of treatment.

![Counteracting thyroid signalling by inhibiting deiodinases in human cartilage development. (A--F) Sections of a representative donor (see online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204739/-/DC1) S4) comparing control (top) and IOP-treated (bottom) chondrogenic human bone marrow-derived stem cell (hBMSC) pellets at 7, 21 and 35 days of treatment. (A, B) Alcian blue staining. (C, D) Immunohistochemical staining of collagen type II. (E, F) Immunohistochemical staining of collagen type X. (A, C and E) Scale bar, 400 μm. (B, D and F) Scale bar, 100 μm. (G) Mean surface area measurements at 7, 21 and 35 days of treatment with N=3 donors in each group. (H) Mean quantitative pixel-intensity measurements (see online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204739/-/DC1) S5) at 7, 21 and 35 days of treatment with N=5 donors in each group. (I) Log2 ratio of *COL2A1* and *COL1A1* with N=5 donors in each group. (J) Mean real-time qRT-PCR analysis of *COL2A1*, *ACAN*, *COL10A1*, *COL1A1, ALPL, ADAMTS5 MMP13*, *RUNX2* and *EPAS1* at 7, 21 and 35 days of treatment in chondrogenic hBMSCs of N=5 donors in each group. The surface area measurement, pixel intensities and level of expression were arbitrarily defined as '1' in the pellets grown under control conditions (white) and the data from the pellets grown in the addition of IOP (grey) are given as mean±SEM. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. SEM\<0.05 are not distinguishable in the figure.](annrheumdis-2013-204739f05){#ANNRHEUMDIS2013204739F5}

Discussion {#s4}
==========

In the current study, we provided insights into how genetic variation at the *DIO2* locus confers risk to OA. As a result of OA-related changes in articular cartilage, loss of epigenetic silencing results in upregulation of *DIO2* expression among *DIO2* rs225014 risk allele carriers ([figures 1](#ANNRHEUMDIS2013204739F1){ref-type="fig"} and [2](#ANNRHEUMDIS2013204739F2){ref-type="fig"}). By applying an in vitro chondrogenesis model with genetically modified hBMSC, it was subsequently shown that genetic upregulation of *DIO2* expression resulted in a marked reduction of the capacity of chondrocytes to deposit ECM components, concurrent with induction of OA-specific markers of cartilage matrix degeneration (*ADAMTS5* and *MMP13*) and mineralisation (*ALPL*) ([figure 3](#ANNRHEUMDIS2013204739F3){ref-type="fig"}). Given their concurrent upregulation, this process is likely mediated via *HIF-2α*/*RUNX2* signalling, a hallmark of the OA disease process.[@R6] [@R24] Moreover, we show that the detrimental effects of *DIO2* upregulation are a result of increased T3 synthesis as reflected by the identical results when adding T3 to the culture medium ([figure 4](#ANNRHEUMDIS2013204739F4){ref-type="fig"}). Given that the effects observed in both treatments are very similar and the fact that the specific downstream effect of D2 action is the conversion of inactive T4 to active T3, we are confident that the reported effects in both experiments are reflecting the same mechanism, although we did not directly assess the levels of the trace element T3 in our in vitro chondrogenesis model. Together our data are in line with our previous observations that carriers of the *DIO2* risk allele are prone to improper endochondral ossification and respective skeletal morphogenesis that could result in subtle malformations of joints or articular cartilage ECM composition.[@R27]

In contrast, we showed that inhibiting deiodinases by addition of IOP contributed to prolonged 'healthy' cartilage homeostasis by virtue of attenuated upregulation of matrix degrading enzymes, a constant *COL2A1/COL1A1* ratio, denser cartilage matrix structure with significant less cellular lacunae, which indicates a reduced propensity of chondrocytes to enter the terminal maturational process ([figure 5](#ANNRHEUMDIS2013204739F5){ref-type="fig"}). In view of these findings, we advocate that attenuation of thyroid signalling by, for example, inhibiting deiodinases could contribute to novel therapeutic options of OA or could improve outcomes of cartilage tissue-engineering approaches. Nevertheless, given that T3 has many and various biological functions, both in the circulation and in a tissue-specific manner, local administration of a thyroid-blocking agent is likely necessary and a challenging aspect. Furthermore, the effect of, for example, IOP on other joint tissues (eg, ligament and synovium) requires investigation. It should be noted that IOP is a general inhibitor of deiodinases and as such could have also inhibited D1 and D3 action. In this respect, expression of *DIO1*, being important mainly in the circulation, is likely absent in cartilage tissues. Furthermore, by inhibiting D3, we prevented the conversion of active T3 to inactive T4, thereby ruling out the effect of T3 depletion due to inactive D2. Despite the beneficial effects of IOP, we observed upregulation of COL10 similar to control cultures reflecting the normal initiation of chondrocyte hypertrophy ([figure 5](#ANNRHEUMDIS2013204739F5){ref-type="fig"}J). Vice versa, we showed that upon addition of T3 chondrocytes directly enter the terminal maturational process towards bone, as reflected by the upregulation of enzymatic breakdown (*ADAMTS5*) and mineralisation (*ALPL, COL1A1*), this without significant induction of COL10 deposition ([figure 4](#ANNRHEUMDIS2013204739F4){ref-type="fig"}E,F). Together, these data indicate that chondrocyte hypertrophy in our model was not necessarily detrimental to cartilage homeostasis in contrast to *DIO2* upregulation. Our data, therefore, indicate that upregulation of *DIO2* does not affect the 'early' hypertrophic expression of *COL10A1* but induces the later 'progression stage' marker *MMP13*, and the 'late stage' markers *ALPL and COL1A1*.[@R28] In our model, we used the expression of *EPAS1* and *RUNX2* to show downstream effects of upregulation of *DIO2* and observed a significant positive association between T3 and *EPAS1*. Although such an observation based on association does not imply a direct causal relationship, recent data of Chatonnet *et al*,[@R29] showed, in a ChIP-seq analysis in mouse C17.2 neural progenitor cells, that *EPAS1* harbours specific thyroid hormone nuclear receptor (THR) binding sites and is directly reactive to thyroid hormone. In view of these data, we advocate that active thyroid hormone, likely by local *DIO2* action, could have an important impact on *EPAS1* upregulation during the pathophysiology of OA. Additional studies are, however, necessary to elucidate whether T3 is directly affecting expression of *EPAS1*, or *RUNX2* for that matter, by binding to a positional thyroid receptor in humans.

Despite the fact that the direction of gene expression changes of *COL2A1* and *MMP13* upon addition of T3 to the culture media appeared consistent with our overall results ([figure 4](#ANNRHEUMDIS2013204739F4){ref-type="fig"}J), the mean differences in expression were not statistically significant across the donors. Most likely this was the result of the considerable heterogeneity in the differential gene expression patterns of these specific genes across donors, especially with respect to timing the respective downregulation and upregulation at consecutive time points (see online supplementary figure S4), a phenomenon generally recognised in the in vitro chondrogenesis models of primary hBMSCs.[@R30]

We detected several CpG dinucleotides across the *DIO2* locus that were differentially methylated between preserved and OA-affected cartilage. Although we have only verified their functionality with respect to *DIO2* expression, we cannot exclude that methylation at these sites regulates expression of more distal genes. We found a consistent positive correlation between methylation at CpG-2031 and *DIO2* expression in articular cartilage among carriers of the rs225014 risk allele, which may not comply with the conventional inverse relation between CpG methylation and gene expression. However, in recent genome-wide approaches, it has been recognised that this conventional relation primarily holds among CpG dinucleotides residing in CpG islands and proximal promoters, whereas gene body and distal enhancer methylation, as is the case for CpG-2031, has been shown to correlate in either direction with gene expression.[@R31]

With respect to our observations of *DIO2* expression in preserved and osteoarthritic cartilage, it should be noted that, in contrast to previously reported high upregulation of *DIO2* expression in osteoarthritic compared with healthy cartilage,[@R5] [@R11] we showed a moderate upregulation in osteoarthritic compared with preserved cartilage of the same joint only among carriers of the rs225014 risk allele ([figure 1](#ANNRHEUMDIS2013204739F1){ref-type="fig"}I). This difference suggests that upregulation of *DIO2* expression may be an early event in OA pathophysiology and might be set to continue progressively among rs225014 risk allele carriers.

We were unable to validate the functionality of a putative CTCF binding site directly at the rs225014 locus nor for that matter the causality of the previously assessed consistent allelic imbalance.[@R11] Possibly, the rs225014 SNP affects three-dimensional chromatin conformations underlying the relation between the rs225014 tagged allelic imbalance and methylation-dependent upregulation of *DIO2* among rs225014 riskallele carriers.

In conclusion, our data provide evidence in humans that genetic predisposition combined with early OA-related changes results in loss of epigenetic silencing of *DIO2*, which likely induces *EPAS1* and *RUNX2* mediated upregulation of cartilage matrix degrading enzymes (*ADAMTS5* and *MMP13*) and mineralisation of matrix (*ALPL* and *COL1A1)*, thereby driving the OA process most distinctly among *DIO2* risk allele carriers. Furthermore, our data show that counteracting the thyroid signalling by inhibiting deiodinases could contribute to needed novel therapeutic approaches of OA.
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